SOURCE: INC Research

INC Research

November 09, 2010 05:00 ET

INC Research Expands Alliance Partnership Executive Team With New VP in Europe

Dr. Manfred Weiler Joins as VP of Alliance Development to Support Growing Interest in Progressive Sponsor-CRO Partnership Models

RALEIGH, NC--(Marketwire - November 9, 2010) - INC Research, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, today announced Dr. Manfred Weiler as VP of Alliance Development based in Europe. Based in Geneva, Dr. Weiler will lead INC Research's European effort to develop new clinical delivery alliances that are aimed at improving outsourced drug development.

"We have experienced a very positive response to our alliance partnership program from sponsors of every type and size because of the economic advantages and focus on mutual goals and alignment," said Alistair Macdonald, executive vice president, Strategic Development at INC Research. "Manfred has the right scientific and strategic background to create alliance models that fit the unique requirements represented across the breadth of our current and prospective customer base. We believe clinical delivery alliances are the natural evolution in our industry and we are dedicated on being drivers of that innovation."

Dr. Weiler has a solid track record in life sciences with experience in building market-leading organizations. Prior to INC Research, he held management positions with SGS Group Management where he led its global CRO Business Development department with teams in Europe, US and Asia. At QIAGEN, he was responsible for the strategy, marketing, and future product developments of a joint venture of QIAGEN GmbH and Becton Dickinson, Inc., Franklin Lakes, USA. Dr. Weiler earned his Ph.D. degree in Biochemistry at the University of Bonn.

INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer. The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.

Dr. Weiler will be at Partnerships in Clinical Trials EU from Nov. 17-18 at the INC Research booth #103. For more information on the company's Alliance Partnership programs, click here. To download "A New Approach to Outsourced Drug Development: How Sponsor-CRO Clinical Delivery Alliances Improve Performance" white paper, click here.

About INC Research, Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com.

Contact Information